Elexacaftor – Tezacaftor – Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study

Rescue of multiple class II CFTR mutations by elexacaftor+ tezacaftor+ivacaftor mediated in part by the dual activities of Elexacaftor as both corrector and potentiator

(2021) Onofrio Laselva et al.   EUROPEAN RESPIRATORY JOURNAL

Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry

(2021) Graham L. Hall et al.   EUROPEAN RESPIRATORY JOURNAL

Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry Cohort study

(2021) Edward F. McKone et al.   EUROPEAN RESPIRATORY JOURNAL

Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration

(2021) Cameron B. Morrison et al.   EUROPEAN RESPIRATORY JOURNAL

A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants

(2021) Guido Veit et al.   Journal of Personalized Medicine

Clinical Effectiveness of Elexacaftor/Tezacftor/Ivacaftor in People with Cystic Fibrosis

(2021) David P Nichols et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung

(2021) Lo M. Sosinski et al.   Journal of Cystic Fibrosis

Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis

(2021) Max C. Petersen et al.   Journal of Cystic Fibrosis

Albumin/Globulin Ratio as Yin–Yang in Rheumatoid Arthritis and Its Correlation to Inflamm-Aging Cytokines

(2021) Yong Chen et al.   Journal of Inflammation Research

Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi®) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells

(2020) Maria Favia et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

(2019) Harry G M Heijerman et al.   LANCET

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

CORK Study in Cystic Fibrosis

(2018) Nicola J. Ronan et al.   CHEST

Dysregulated Calcium Homeostasis in Cystic Fibrosis Neutrophils Leads to Deficient Antimicrobial Responses

(2018) Frank H. Robledo-Avila et al.   JOURNAL OF IMMUNOLOGY

Application of albumin/globulin ratio in elderly patients with acute exacerbation of chronic obstructive pulmonary disease

(2018) Jinqiu Qin et al.   Journal of Thoracic Disease

Cystic fibrosis: current therapeutic targets and future approaches

(2017) Misbahuddin M. Rafeeq et al.   Journal of Translational Medicine

Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor

(2016) Preston E. Bratcher et al.   Journal of Cystic Fibrosis

Regulatory T-Cell Impairment in Cystic Fibrosis Patients with ChronicPseudomonasInfection

(2015) Andreas Hector et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

(2014) Steven M. Rowe et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor

(2014) Sonya L. Heltshe et al.   CLINICAL INFECTIOUS DISEASES

A Th17- and Th2-skewed Cytokine Profile in Cystic Fibrosis Lungs Represents a Potential Risk Factor forPseudomonas aeruginosaInfection

(2013) Kerstin Tiringer et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Immune Responses in Cystic Fibrosis

(2012) Dmitry Ratner et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation

(2011) Bonnie W. Ramsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

The prevalence of cystic fibrosis in the European Union

(2008) Philip M. Farrell   Journal of Cystic Fibrosis